Analysis
04 MAR 2026
The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors
11 DEC 2025
Checkbook Darwinism: Why Merck and Roche Are Paying ‘Panic Premiums’ to Avert Extinction